Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Haleh ChehrehgoshaMasoud Reza SohrabiFaramarz Ismail-BeigiMojtaba MalekMohammad Reza BabaeiFarhad ZamaniHossein AjdarkoshMahmood KhoonsariAfshin Eshghi FallahMohammad Ebrahim Khamseh

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

Iranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.

Keyphrases

clinical trial
double blind
placebo controlled
type diabetes
insulin resistance
liver fibrosis
phase ii
phase iii
study protocol
glycemic control
high fat diet
open label
phase ii study
cardiovascular disease
high fat diet induced
adipose tissue
skeletal muscle
metabolic syndrome